Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Pacira BioSciences, Inc. (PCRX) had Revenue of $700.97M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$700.97M
Net Income	$-99.56M
Cost of Goods Sold	$170.43M
Gross Profit	$530.54M
Operating Expenses	$774.34M
Operating Income	$-73.37M
Non-Operating Income/Expense	$10.27M
Pre-Tax Income	$-63.11M
Normalized Pre-Tax Income	$-63.11M
Income after Taxes	$-99.56M
Income from Continuous Operations	$-99.56M
Consolidated Net Income/Loss	$-99.56M
Normalized Income after Taxes	$-99.56M
EBIT	$-73.37M
EBITDA	$8.64M
Weighted-Average Shares Outstanding (Basic)	46.24M
Weighted-Average Shares Outstanding (Diluted)	46.24M
Earnings per Share (EPS) (Basic)	$-2.15
Earnings per Share (EPS) (Diluted)	$-2.15
Balance Sheet Financials
Current Assets	$745.13M
Property, Plant, and Equipment	$167.17M
Long-Term Assets	$808.39M
Total Assets	$1.55B
Current Liabilities	$309.92M
Long-Term Debt	$383.55M
Long-Term Liabilities	$465.25M
Total Liabilities	$775.17M
Common Equity	$778.35M
Tangible Shareholders Equity	$352.38M
Shareholders Equity	$778.35M
Common Shares Outstanding	46.24M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$189.39M
Cash Flow from Investing Activities	$-83.28M
Cash Flow from Financial Activities	$17.36M
Beginning Cash	$153.30M
End Cash	$276.77M
Increase/Decrease in Cash	$123.48M
Stock-Based Compensation	$51.17M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.40
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.33
Debt to Equity Ratio	0.75
Gross Margin	75.69%
Operating Margin	-10.47%
EBIT Margin	-10.47%
EBITDA Margin	1.23%
Pre-Tax Profit Margin	-9.00%
Profit Margin	-14.20%
Free Cash Flow	$178.75M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.45
Inventory Turnover	1.36
Receiveable Turnover	6.19
Days Sales in Receivables	59.00
Return on Equity	-12.79%
Return on Tangible Equity	-28.25%
Return on Assets	-6.41%
Return on Investments	-8.57%
Book Value Per Share	$16.83
Free Cash Flow per Share	$3.87
Operating Cash Flow per Share	$4.10

Data from Zacks Investment Research, Inc.